DPP IV Inhibitors - Global Strategic Business Report - Analyzed by Drugs, Sales & Number of Perscriptions - Research and Markets

DUBLIN, May 26, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "DPP IV Inhibitors - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. The report profiles 23 companies including many key and niche players such as -

• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co, Inc.
• Mitsubishi Tanabe Pharma Corporation

Key Topics Covered:

1. INDUSTRY OVERVIEW

2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS

3. DIABETES INCIDENCE AND PREVALENCE

4. DPP-IV INHIBITORS

5. PRODUCT APPROVALS/INTRODUCTIONS

6. RECENT INDUSTRY ACTIVITY

7. FOCUS ON SELECT GLOBAL PLAYERS

• AstraZeneca Plc.
  
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
  
• Merck & Co, Inc.
  
• Mitsubishi Tanabe Pharma Corporation
  
• Novartis AG
  
• Takeda Pharmaceutical Company Limited

8. GLOBAL MARKET PERSPECTIVE

For more information visit http://www.researchandmarkets.com/research/sdv4jl/dpp_iv_inhibitors

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]